Category - Developments

Developments

Neural shares commence trading on Frankfurt Stock Exchange

Neural Therapeutics (CSE:NURL) announced that shares of the company have commenced trading on the Frankfurt Stock Exchange under symbol “M6B”. The company is developing therapeutics to address mental illnesses related...

March 31, 2025

Developments

Leap reports positive Phase 2 data of sirexatamab in MSS CRC

Leap Therapeutics (NASDAQ:LPTX) announced positive updated data from its Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy, compared to bevacizumab...

March 26, 2025

Developments

Coya reports progress of first-in-class Treg-derived exosome program

Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic...

March 26, 2025

Developments

Sunshine enters agreement to market generic antibiotics in Canada

Sunshine Biopharma (NASDAQ:SBFM) announced that it has signed an agreement to market two new generic antibiotics in Canada through its wholly owned Canadian subsidiary, Nora Pharma, subject to regulatory approval...

March 25, 2025

Developments

Oncotelic completes Phase 1 study of OT-101 and IL-2 in metastatic solid tumors

Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors. According to Oncotelic, this announcement coincides with a...

March 25, 2025

Developments

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis

Can-Fite BioPharma (NYSE American:CANF) announced that it has initiated a pivotal Phase 3 study of its oral drug Piclidenoson for the treatment of psoriasis, with FDA- and EMA-approved protocol. According to Can-Fite...

March 24, 2025

Developments

First patients recruited into Ondine’s Steriwave ICU pilot study

Ondine Biomedical (LON:OBI) announced the initiation of patient recruitment for an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. The company states that...

March 20, 2025

Developments

USPO issues NOA to Sonnet for second IL-18 protein patent

Sonnet BioTherapeutics (NASDAQ:SONN) announced that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) for a second patent in the IL-18 variant protein field. According to...

March 19, 2025

Developments

Bioxytran signs NDA with UGA to evaluate galectin antagonist for bird flu

Bioxytran (QTCQB:BIXT) announced that it has signed a non-disclosure agreement (NDA) with the board of regents of the University System of Georgia, University of Georgia (UGA), to collaborate on evaluating its galectin...

March 19, 2025

Developments

Final patient enrolled in Biofrontera’s Phase 3 trial of Ameluz in AKs

Biofrontera (NASDAQ:BFRI) announced completion of patient enrollment in the Phase 3 study of Ameluz topical gel for the treatment of Actinic Keratoses (AKs) on the extremities, neck, and trunk with photodynamic therapy...

March 18, 2025

Category - Developments

Subscribe